Current advances in targeted therapies for metastatic gastric cancer: improving patient care

Aguiar, Pedro Nazareth Jr.; Muniz, Thiago Pimentel; Miranda, Raelson Rodrigues; Tadokoro, Hakaru; Forones, Nora Manoukian; Monteiro, Inês-de-Paula; Castelo-Branco, Pedro; Janjigian, Yelena Y.; Mello, Ramon Andrade de

http://hdl.handle.net/10400.1/9768

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
H.9768.pdf		1.77 MB	Adobe PDF	Ver/Abrir

Contacte-nos

Autores

Aguiar, Pedro Nazareth Jr.

Muniz, Thiago Pimentel

Miranda, Raelson Rodrigues

Tadokoro, Hakaru

Forones, Nora Manoukian

Monteiro, Inês-de-Paula

Castelo-Branco, Pedro

Janjigian, Yelena Y.

Mello, Ramon Andrade de

Resumo(s)

In this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use. Furthermore, it is necessary to understand that gastric tumors are heterogeneous; therefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.

URI

http://hdl.handle.net/10400.1/9768

Editora

Future Medicine

DOI

10.2217/fon.15.348

Coleções

FCB2-Artigos (em revistas ou actas indexadas)

Métricas Alternativas

Ver registo completo